Effect of radium-223 dichloride (Ra-223) on risk for and duration of hospitalization in ALSYMPCA by docetaxel (D) subgroup.

被引：0
|
作者：
Cislo, Paul
Reuning-Scherer, Jonathan D.
机构：
[1] Bayer HealthCare, Whippany, NJ USA
[2] Yale Univ, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 07期
关键词：
D O I：
10.1200/jco.2015.33.7_suppl.254
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
254
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Radium-223 dichloride (Ra-223) hematologic and 1.5-year posttreatment safety in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from ALSYMPCA
    Conti, Peter
    Michalski, Jeff
    Skjorestad, Irene
    Wahba, Mona
    Nilsson, Sten
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55
  • [32] A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.
    Morris, Michael J.
    De Wit, Ronald
    Vogelzang, Nicholas J.
    Tagawa, Scott T.
    Higano, Celestia S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.
    Morris, Michael J.
    De Wit, Ronald
    Vogelzang, Nicholas J.
    Tagawa, Scott T.
    Higano, Celestia S.
    Hamberg, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] A phase Ill trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.
    Morris, Michael J.
    De Wit, Ronald
    Vogelzang, Nicholas J.
    Tagawa, Scott T.
    Higano, Celestia S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [35] Effect of docetaxel on safety and efficacy of radium-223 Comment
    Den, Robert B.
    Kelly, W. Kevin
    LANCET ONCOLOGY, 2014, 15 (12): : 1292 - 1293
  • [36] Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial
    Vogelzang, Nicholas J.
    Coleman, Robert E.
    Michalski, Jeff M.
    Nilsson, Sten
    O'Sullivan, Joe M.
    Parker, Christopher
    Widmark, Anders
    Thuresson, Marcus
    Xu, Lei
    Germino, Joseph
    Sartori, Oliver
    CLINICAL GENITOURINARY CANCER, 2017, 15 (01) : 42 - 52
  • [37] Hematologic safety of Ra-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases from the phase III ALSYMPCA trial
    Parker, Chris
    Garcia-Vargas, Jose E.
    O'Bryan-Tear, C. Gillies
    Fang, Fang
    Vogelzang, Nicholas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [38] UTILIZATION OF RADIUM-223 DICHLORIDE (RA-223) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CANADA: A REAL-WORLD RETROSPECTIVE STUDY
    Lapierre, M.
    Fraelic, A.
    VALUE IN HEALTH, 2016, 19 (03) : A162 - A162
  • [39] Safety and effectiveness of radium-223 dichloride (Ra-223) in patients with mCRPC in real-world setting: A Japanese post-marketing study (PMS)
    Takahashi, Shunji
    Kakehi, Yoshiyuki
    Masumori, Naoya
    Hosono, Makoto
    Kinuya, Seigo
    Okayama, Yutaka
    Sunaya, Toshiyuki
    Okumura, Masafumi
    Uemura, Hirotsugu
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [40] Time to first skeletal-related event (SRE) with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases: ALSYMPCA trial stratification factors analysis
    Coleman, R.
    Fossa, S.
    Chodacki, A.
    Wedel, S.
    Bruland, O.
    Staudacher, K.
    Garcia-Vargas, J.
    Sartor, O.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S688 - S688
12345